These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32319656)

  • 1. Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF.
    Liu X; Li Z; Li M; Chai J; He S; Wu J; Xu J
    Oncol Rep; 2020 Jul; 44(1):360-370. PubMed ID: 32319656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Juglone potentiates BRAF inhibitor‑induced apoptosis in melanoma through reactive oxygen species and the p38‑p53 pathway.
    Li Z; Liu X; Li M; Chai J; He S; Wu J; Xu J
    Mol Med Rep; 2020 Jul; 22(1):566-574. PubMed ID: 32377702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
    Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
    Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
    Haq R; Yokoyama S; Hawryluk EB; Jönsson GB; Frederick DT; McHenry K; Porter D; Tran TN; Love KT; Langer R; Anderson DG; Garraway LA; Duncan LM; Morton DL; Hoon DS; Wargo JA; Song JS; Fisher DE
    Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4321-6. PubMed ID: 23447565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF
    Hartman ML; Czyz M
    Arch Dermatol Res; 2020 Jul; 312(5):385-392. PubMed ID: 31624899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
    Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
    PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
    Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
    Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells.
    Bauer D; Werth F; Nguyen HA; Kiecker F; Eberle J
    Cell Death Dis; 2017 Feb; 8(2):e2594. PubMed ID: 28151482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.
    Das I; Gad H; Bräutigam L; Pudelko L; Tuominen R; Höiom V; Almlöf I; Rajagopal V; Hansson J; Helleday T; Egyházi Brage S; Warpman Berglund U
    Cell Death Differ; 2020 Jul; 27(7):2081-2098. PubMed ID: 31919461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MITF Modulates Therapeutic Resistance through EGFR Signaling.
    Ji Z; Erin Chen Y; Kumar R; Taylor M; Jenny Njauw CN; Miao B; Frederick DT; Wargo JA; Flaherty KT; Jönsson G; Tsao H
    J Invest Dermatol; 2015 Jul; 135(7):1863-1872. PubMed ID: 25789707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status.
    Komina AV; Palkina NV; Aksenenko MB; Lavrentev SN; Moshev AV; Savchenko AA; Averchuk AS; Rybnikov YA; Ruksha TG
    Melanoma Res; 2019 Oct; 29(5):544-548. PubMed ID: 31116162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.
    Madorsky Rowdo FP; Barón A; Gallagher SJ; Hersey P; Emran AA; Von Euw EM; Barrio MM; Mordoh J
    Int J Oncol; 2020 Jun; 56(6):1429-1441. PubMed ID: 32236593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF
    Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
    Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
    Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
    Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
    Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HI-511 overcomes melanoma drug resistance
    Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
    Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
    Vergani E; Vallacchi V; Frigerio S; Deho P; Mondellini P; Perego P; Cassinelli G; Lanzi C; Testi MA; Rivoltini L; Bongarzone I; Rodolfo M
    Neoplasia; 2011 Dec; 13(12):1132-42. PubMed ID: 22241959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
    Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
    Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
    Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
    Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.